Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) EBIT (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of EBIT data on record, last reported at -$7.2 million in Q4 2025.

  • For Q4 2025, EBIT rose 36.97% year-over-year to -$7.2 million; the TTM value through Dec 2025 reached -$12.2 million, up 81.52%, while the annual FY2025 figure was -$12.2 million, 81.52% up from the prior year.
  • EBIT reached -$7.2 million in Q4 2025 per VRCA's latest filing, down from $1.6 million in the prior quarter.
  • Across five years, EBIT topped out at $1.6 million in Q3 2025 and bottomed at -$23.9 million in Q3 2023.
  • Average EBIT over 5 years is -$9.8 million, with a median of -$8.8 million recorded in 2021.
  • The widest YoY moves for EBIT: up 112.29% in 2022, down 12450.0% in 2022.
  • A 5-year view of EBIT shows it stood at -$8.5 million in 2021, then rose by 26.67% to -$6.2 million in 2022, then plummeted by 272.5% to -$23.1 million in 2023, then skyrocketed by 50.68% to -$11.4 million in 2024, then skyrocketed by 36.97% to -$7.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$7.2 million in Q4 2025, $1.6 million in Q3 2025, and $1.5 million in Q2 2025.